Bufuralol Hydrochloride: Non-Selective β-Adrenergic Antagonist for Cardiovascular Pharmacology

Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline small molecule primarily acting as a non-selective β-adrenergic receptor antagonist, exhibiting partial intrinsic sympathomimetic activity and membrane-stabilizing properties (APExBIO). It demonstrates prolonged inhibition of exercise-induced heart rate comparable to propranolol in clinical settings. In vitro, bufuralol is used for probing β-adrenoceptor signaling and drug metabolism in advanced human stem cell-derived intestinal organoids (Saito et al., 2025). The compound’s solubility profile and storage requirements enable reliable integration into cardiovascular pharmacology workflows. Its unique dual action and compatibility with organoid models distinguish it from conventional β-blockers.

Biological Rationale

The β-adrenergic signaling pathway is central to cardiovascular homeostasis, modulating heart rate, contractility, and vascular tone. Non-selective β-adrenergic receptor antagonists, including bufuralol hydrochloride, inhibit both β1 and β2 adrenoceptors, impacting multiple cardiovascular endpoints (Saito et al., 2025). Human induced pluripotent stem cell-derived intestinal organoids replicate key aspects of human metabolism and pharmacokinetics, providing a robust model for evaluating orally administered cardiovascular drugs (Bufuralol hydrochloride in Organoid Models). Bufuralol hydrochloride’s partial agonist effects allow it to serve as both a functional antagonist and a probe for residual β-adrenergic activity, supporting mechanistic studies in disease and homeostasis.

Mechanism of Action of Bufuralol hydrochloride

Bufuralol hydrochloride binds competitively to β1 and β2 adrenergic receptors, thereby blocking catecholamine-mediated signal transduction. Unlike pure antagonists, it displays partial intrinsic sympathomimetic activity (ISA), which can induce tachycardia in animal models depleted of endogenous catecholamines (APExBIO). In vitro assays reveal that bufuralol stabilizes cell membranes, further distinguishing its pharmacological profile from classical β-blockers. The compound’s inhibitory effect on exercise-induced heart rate elevation is quantitatively similar to propranolol in controlled clinical studies (Bufuralol Hydrochloride: Pioneering β-Adrenergic Modulation), supporting its use in translational research.

Evidence & Benchmarks

• Bufuralol hydrochloride inhibits both β1 and β2 adrenoceptors, confirmed in receptor binding and functional assays (Saito et al., 2025).
• Partial intrinsic sympathomimetic activity is demonstrated by the induction of tachycardia in catecholamine-depleted animal models (APExBIO).
• It exhibits membrane-stabilizing effects in vitro, aiding in the functional dissection of β-adrenergic signaling (Next-Gen Probe for Beta-Adrenoceptor Signaling).
• Human pluripotent stem cell-derived intestinal organoids metabolize bufuralol via CYP enzymes, enabling pharmacokinetic and transporter studies in human-relevant contexts (Saito et al., 2025).
• Bufuralol hydrochloride’s effect on exercise-induced heart rate is sustained for several hours post-administration in humans, matching propranolol’s efficacy (Bufuralol Hydrochloride: Pioneering β-Adrenergic Modulation).

Applications, Limits & Misconceptions

Bufuralol hydrochloride’s non-selective blockade and partial agonist properties make it a versatile tool in cardiovascular pharmacology research. Its use spans from functional assays in tissue and cell models to advanced pharmacokinetic studies in stem cell-derived organoids (Intestinal Organoid Models). This article extends prior discussions by focusing on standardized workflows, comparative benchmarks, and integration with next-generation human in vitro systems, which are only briefly addressed in earlier reviews such as Bufuralol hydrochloride (SKU C5043): Reliable β-Adrenergi....

Common Pitfalls or Misconceptions

• Selective Antagonism: Bufuralol hydrochloride is non-selective and should not be used where β1-specific antagonism is required.
• Long-Term Solution Stability: Aqueous or DMSO solutions of bufuralol hydrochloride degrade over time; solutions must be used promptly and not stored long-term (APExBIO).
• Species Differences: Pharmacokinetic data from animal models may not extrapolate directly to human contexts due to metabolic differences, underscoring the value of human organoid systems (Saito et al., 2025).
• Membrane-Stabilizing Effects: These effects can confound results in electrophysiology or cytotoxicity assays if not properly controlled (Reliable β-Adrenergi...).
• Intrinsic Activity: Its partial agonist (ISA) properties may mask full antagonism in some experimental settings.

Workflow Integration & Parameters

Bufuralol hydrochloride is supplied by APExBIO (SKU C5043) as a crystalline powder. The molecular weight is 297.8 g/mol, and the chemical formula is C16H23NO2·HCl. It is soluble up to 15 mg/ml in ethanol, 10 mg/ml in DMSO, and 15 mg/ml in dimethyl formamide. For optimal stability, the product should be stored at -20°C. Fresh solutions are recommended for each experiment; prolonged storage of dissolved material leads to degradation. In cardiovascular pharmacology and β-adrenergic modulation studies, bufuralol is used to dissect receptor-specific signaling in organoids, tissue slices, and cell lines. For advanced in vitro models, such as human stem cell-derived intestinal organoids, bufuralol’s metabolism can be tracked to benchmark CYP activity and transporter function (Saito et al., 2025).

This article builds upon the recent review in Bufuralol Hydrochloride in Human Intestinal Organoid-Based Models, providing a more detailed protocol for integrating bufuralol into organoid assays and highlighting the compound’s membrane-stabilizing side effects, which remain underexplored in most workflows.

Conclusion & Outlook

Bufuralol hydrochloride is a validated non-selective β-adrenergic receptor blocker with partial intrinsic sympathomimetic activity and membrane-stabilizing effects. Its ability to probe beta-adrenoceptor signaling and pharmacokinetics in advanced human organoid models positions it as a critical tool for translational cardiovascular research (product information). As human-relevant in vitro systems become standard for drug metabolism and disease modeling, bufuralol hydrochloride’s utility will further expand. Researchers are encouraged to leverage its dual-action profile while controlling for partial agonist effects and ensuring proper solution handling.